75 related articles for article (PubMed ID: 38702146)
1. Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.
Ramamurthy C; Wheeler KM; Trecarten S; Hassouneh Z; Ji N; Lee Y; Svatek RS; Mukherjee N
J Cancer Immunol (Wilmington); 2024; 6(1):29-39. PubMed ID: 38784962
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax induces BCL-2-dependent Treg to TH17 plasticity to enhance the antitumor efficacy of anti-PD-1 checkpoint blockade.
Liao R; Hsu JY; Aboelella NS; McKeever JA; Thomas-Toth AT; Koh AS; LaBelle JL
Cancer Immunol Res; 2024 May; ():. PubMed ID: 38810242
[TBL] [Abstract][Full Text] [Related]
3. Buena VISTA: a promising outlook on targeting immune checkpoint regulators to combat sepsis.
Mott MD; Trusiano B; Allen IC
J Leukoc Biol; 2024 May; 115(6):1002-1004. PubMed ID: 38526166
[No Abstract] [Full Text] [Related]
4. Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.
Volz B; Schmidt M; Heinrich K; Kapp K; Schroff M; Wittig B
Mol Ther Oncolytics; 2016; 3():15023. PubMed ID: 27119114
[TBL] [Abstract][Full Text] [Related]
5. Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control.
Walshaw RC; Honeychurch J; Choudhury A; Illidge TM
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):27-37. PubMed ID: 32339645
[TBL] [Abstract][Full Text] [Related]
6. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
7. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
Jeon D; Hill E; Moseman JE; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression.
Jeon D; McNeel DG
Oncoimmunology; 2022; 11(1):2054758. PubMed ID: 35340661
[TBL] [Abstract][Full Text] [Related]
9. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
Chandramohan V; Bao X; Yu X; Parker S; McDowall C; Yu YR; Healy P; Desjardins A; Gunn MD; Gromeier M; Nair SK; Pastan IH; Bigner DD
J Immunother Cancer; 2019 May; 7(1):142. PubMed ID: 31142380
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
11. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
[TBL] [Abstract][Full Text] [Related]
12. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
13. Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant.
Wang B; Ou Z; Zhong W; Huang L; Liao W; Sheng Y; Guo Z; Chen J; Yang W; Chen K; Huang X; Yang T; Lin T; Huang J
Cancer Immunol Res; 2023 Dec; 11(12):1656-1670. PubMed ID: 37847894
[TBL] [Abstract][Full Text] [Related]
14. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer.
Rolfo C; Giovannetti E; Martinez P; McCue S; Naing A
NPJ Precis Oncol; 2023 Mar; 7(1):26. PubMed ID: 36890302
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
